Positive News SentimentPositive NewsNASDAQ:CLYM Climb Bio (CLYM) Stock Price, News & Analysis $1.37 +0.02 (+1.48%) As of 07/11/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Climb Bio Stock (NASDAQ:CLYM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Climb Bio alerts:Sign Up Key Stats Today's Range$1.32▼$1.3950-Day Range$1.17▼$1.3952-Week Range$1.05▼$9.21Volume245,280 shsAverage Volume378,408 shsMarket Capitalization$92.58 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingBuy Company Overview Climb Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of targeted protein degraders for the treatment of cancer and other serious diseases. The company is leveraging an integrated drug discovery platform that combines medicinal chemistry, structural biology and proprietary assays to identify small molecules capable of directing disease-causing proteins to the cell’s natural degradation machinery. With a primary emphasis on oncology, Climb Bio’s lead programs are designed to address high-unmet-need targets that have historically proven difficult to modulate with traditional small-molecule inhibitors or biologics. Since its formation as an independent public company, Climb Bio has built a pipeline that spans multiple therapeutic modalities and target classes. Its research and development efforts are supported by state-of-the-art laboratories in the United States, where multidisciplinary teams work on early-stage discovery as well as translational research. The company has also established strategic partnerships to broaden its scientific capabilities and expedite the advancement of its most promising candidates toward clinical evaluation. Through these collaborations, Climb Bio aims to capitalize on external expertise while retaining core control over its proprietary chemistry and screening platforms. Climb Bio was founded by a group of industry veterans and academic scientists with deep experience in drug discovery, structural biology and oncology. The senior management team includes executives who have previously led successful biotech ventures and overseen late-stage clinical programs. Based in the U.S., with outreach to select research centers in Europe and Asia, the company combines global scientific collaboration with a nimble organizational structure. This approach is intended to streamline decision-making and foster rapid progress from target discovery through clinical development.AI Generated. May Contain Errors. Read More Climb Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreCLYM MarketRank™: Climb Bio scored higher than 70% of companies evaluated by MarketBeat, and ranked 295th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingClimb Bio has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageClimb Bio has only been the subject of 2 research reports in the past 90 days.Read more about Climb Bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Climb Bio are expected to grow in the coming year, from ($1.57) to ($0.66) per share.Price to Book Value per Share RatioClimb Bio has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Climb Bio's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CLYM. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldClimb Bio does not currently pay a dividend.Dividend GrowthClimb Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for CLYM. News and Social Media3.8 / 5News Sentiment1.80 News SentimentClimb Bio has a news sentiment score of 1.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Climb Bio this week, compared to 1 article on an average week.Search Interest1 people have searched for CLYM on MarketBeat in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Climb Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,540.00 in company stock.Percentage Held by InsidersOnly 0.80% of the stock of Climb Bio is held by insiders.Percentage Held by Institutions69.76% of the stock of Climb Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Climb Bio's insider trading history. Receive CLYM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Climb Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address CLYM Stock News HeadlinesClimb Bio appoints Edgar D. Charles as Chief Medical OfficerJune 18, 2025 | msn.comClimb Bio Appoints Cindy Driscoll as Finance VPJune 18, 2025 | tipranks.comTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.July 12 at 2:00 AM | Paradigm Press (Ad)Oppenheimer Initiates Coverage of Climb Bio (CLYM) with Outperform RecommendationJune 7, 2025 | msn.comCLYM Climb Bio, Inc.May 30, 2025 | seekingalpha.comBTIG sets Climb Bio stock Buy rating, $7 targetMay 23, 2025 | investing.comClimb Bio, Inc.: Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 20, 2025 | finanznachrichten.deClimb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 19, 2025 | globenewswire.comSee More Headlines CLYM Stock Analysis - Frequently Asked Questions How have CLYM shares performed this year? Climb Bio's stock was trading at $1.80 on January 1st, 2025. Since then, CLYM shares have decreased by 23.9% and is now trading at $1.37. How were Climb Bio's earnings last quarter? Climb Bio, Inc. (NASDAQ:CLYM) announced its earnings results on Wednesday, May, 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.16. How do I buy shares of Climb Bio? Shares of CLYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/14/2025Today7/12/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CLYM Previous SymbolNASDAQ:CLYM CIK1768446 Webclimbbio.com Phone866-857-2596FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Price Target for Climb Bio$9.00 High Price Target$10.00 Low Price Target$7.00 Potential Upside/Downside+556.9%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($2.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$73.90 million Net MarginsN/A Pretax MarginN/A Return on Equity-43.95% Return on Assets-42.94% Debt Debt-to-Equity RatioN/A Current Ratio14.25 Quick Ratio14.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.15 per share Price / Book0.43Miscellaneous Outstanding Shares67,580,000Free Float67,035,000Market Cap$92.58 million OptionableN/A Beta-0.13 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:CLYM) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.